Declan Murphy on Theranostics and Future of PSMA PET/CT for Prostate Cancer

Video

Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.

From the 2020 SUO Meeting, Professor Declan Murphy, of the Peter MacCallum Cancer Centre, spoke with CancerNetwork about the future of PSMA PET/CT imaging and the looming advancements with PSMA theranostics.

Transcription:

But finally, the really, really big area looming on the horizon is PSMA theranostics. So, because we know the PSMA molecule is overexpressed on aggressive prostate cancer, especially for example metastatic castration-resistant prostate cancer, we can actually target that using theranostic agents. So, when the PET scan shows lots of this avidity and so on, we can then label a PSMA molecule with a therapy molecule like for example lutetium-177, a beta-emitter. Effectively you can inject this combined ligand with the PSMA ligand and the lutetium, and the lutetium will be brought to the sites of disease.

So, I think this area will be one in which we will have many, many opportunities to see how we can improve outcomes for patients because these therapy projects will be easier to measure in terms of oncologic outcomes compared to the diagnostic opportunities we already have with PSMA PET/CT. So, I think it’s a very exciting decade or more ahead for those interested in PSMA and prostate cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content